ESMO 2019 | PARP inhibitors for ovarian cancer – room for improvement with HRD testing

Thomas Helleday

Thomas Helleday, MD, PhD, Karolinska Institute, Stockholm, Sweden & University of Sheffield, Sheffield, UK, stresses the need to improve homologous recombination deficiency (HRD) testing to provide more effective treatment with PARP inhibitors. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video